Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sharon Benzeno Sells 11,034 Shares

by · The Cerbat Gem

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Sharon Benzeno sold 11,034 shares of Adaptive Biotechnologies stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $21.00, for a total value of $231,714.00. Following the sale, the insider owned 272,751 shares in the company, valued at $5,727,771. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

  • On Monday, June 29th, Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52.

Adaptive Biotechnologies Stock Up 0.2%

Shares of Adaptive Biotechnologies stock traded up $0.05 on Tuesday, hitting $21.45. 3,421,196 shares of the company’s stock traded hands, compared to its average volume of 3,848,816. Adaptive Biotechnologies Corporation has a 52-week low of $9.96 and a 52-week high of $21.64. The stock has a market cap of $3.43 billion, a P/E ratio of -65.00 and a beta of 2.15. The firm’s 50-day moving average is $15.66 and its 200 day moving average is $15.74.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.20) earnings per share. Equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Analysts Set New Price Targets

ADPT has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Morgan Stanley reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. TD Cowen increased their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, JPMorgan Chase & Co. lowered their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.50.

Get Our Latest Analysis on ADPT

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD lifted its holdings in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the period. Invesco Ltd. grew its holdings in shares of Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after purchasing an additional 2,216,595 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Adaptive Biotechnologies by 544.0% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after purchasing an additional 2,062,282 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

Recommended Stories